gamma-aminobutyric acid type A receptor subunit rho3Genealiases: []
Q-omics provides the consensus-scored GABRR3 profile across patient tissues and cancer cell-line models. GABRR3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, GABRR3 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, GABRR3 RNA expression shows 11,888 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, THCA, and TGCT as cancer lineages where GABRR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GABRR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GABRR3 survival associations across molecular data types. GABRR3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GABRR3 RNA expression–survival associations across cancer types. High GABRR3 expression shows unfavorable associations in KIRC, KICH, DLBC and KIRP, but favorable associations in LUAD and CESC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for GABRR3 RNA expression.
This table summarizes GABRR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GABRR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GABRR3 shows lower tumor expression in THCA and KIRC and higher tumor expression in LIHC, BRCA and LUAD. The THCA box plot shows higher GABRR3 RNA expression in normal versus tumor tissue (log2 FC = −0.063, t-test p < 0.001).
This table shows molecular features associated with GABRR3 in patient tissues and cancer cell lines. In patient samples, GABRR3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GABRR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
